The spread of the COVID-19 virus in Nigeria took a new turn in the month of May with an exponential increase in the number of new cases released by the Nigeria Centre for Disease Control.
According to an analysis carried out by Nigeria’s leading media intelligence and Public relations audit agency, P+ Measurement Services, a total of 8230 new cases were recorded in the month of May, 2688 people were discharged and 229 deaths were recorded. This shows a great increase when compared to data reported for the month of April. P+ Measurement had reported a total of 1795 new cases, 308 discharged cases and 55 deaths in the month of April.
In general, a total of 10,162 cases have been confirmed, 3,007 people discharged and 287 deaths were recorded in 35 states and the Federal Capital Territory while active cases stood at 6,868.
With the latest figures available on NCDC website, Lagos state total confirmed has risen to 4943, followed by Kano (954), Abuja at 660, Katsina (364), Oyo (292), Edo (284), Ogun (278), Borno (271), Jigawa (270), Kaduna (258), Bauchi (238), Rivers (206), Gombe (161), Sokoto (116), Plateau (105).
Kwara State has recorded 88 cases, Delta (83), Zamfara (76), Nasarawa (62), Yobe (52), Akwa Ibom and Osun (45), Ebonyi (40), Adamawa (38), Imo (36), Kebbi (33), Niger (32), Ondo (25), Bayelsa (21), Ekiti (20), Taraba and Enugu (18), Anambra (11), Abia (10), Benue (7), while Kogi state has recorded 2 cases.
This shows that Lagos has remained the epicentre of the novel virus in the country, and despite the increasing figures in the new cases, there have been media reports that government is mulling opening more social gatherings, particularly religious centres. This has continued to raise more concerns among some citizens who hold diverse views on opening these places up.
With the United States of America surpassing the 100,000 deaths estimation by experts and as Brazil became the epicentre of the virus, the World Health Organization (WHO) has revealed that it is focusing its attention on any available drug or vaccine to fight the virus while pausing the trial of hydroxychloroquine in patients over safety concerns.